4D pharma plc (LON: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today announced the final results for the Group for the year ended 31 December 2018.
David Norwood, Chairman of 4D pharma, commented “I am pleased to be able to announce the Group’s final results for the year ended 31 December 2018. The year has seen significant progress towards our goal of producing Live Biotherapeutics as safe and effective therapies. I would like to thank everyone in the Group for their contribution to the progress we have made in 2018.”
Financial highlights for the year:
· Net assets of £45.8 million (2017: £69.8 million)
· Cash and cash equivalents (including cash on deposit) of £26.2 million (2017: £50.0 million)
· Total comprehensive loss after tax of £24.3 million (2017: £19.4 million)
· Adjusted loss per share of 36.17 pence (2017: 26.08 pence)
· Basic and diluted loss per share of 36.17 pence (2017: 31.41 pence)
Operational highlights for the year:
Oncology:
· Clinical collaboration with Merck & Co., Inc. to evaluate MRx0518 in combination with Keytruda® (pembrolizumab)
· Partnership with University of Texas MD Anderson Cancer Center to evaluate our oncology candidates in various cancer settings
· Progression of lead oncology candidate, MRx0518, into Phase I/II clinical studies
o Phase I/II combination study with KEYTRUDA® (pembrolizumab) in solid tumours
o Phase I monotherapy study of MRx0518 for solid tumours in a neoadjuvant setting
Gastrointestinal disease:
· Initiation of Phase II clinical study of Blautix® in Irritable Bowel Syndrome
· Successful completion of Phase Ib Thetanix® study in paediatric Crohn’s disease
Respiratory disease:
· Regulatory progress for a Phase I/II study in asthma, expected to commence in coming months
Research:
· Progression in identifying the efficacy and mechanism of our core focus Live Biotherapeutics leading to significant publications
· Identification of two lead candidates for Parkinson’s disease via the MicroRx® platform
· Increased intellectual property portfolio with 56 patent families and over 400 patents granted
Duncan Peyton, Chief Executive Officer, commented “2018 has been an exciting year for us with a number of clinical and research goals achieved. I look forward to the coming year as we prepare for clinical readouts that could revolutionise our quest to make microbiome medicines a reality for patients. “
The Annual Report, together with a notice of the Company’s Annual General Meeting, will be posted to shareholders and made available on the Company’s website, by 28 May 2019. The Annual General Meeting will be held on Thursday 20 June 2019 at 10 a.m. in the Chicago Room, Sofitel, Terminal 5, Wentworth Drive, London Heathrow Airport, Hounslow TW6 2GD.
